Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

ASHLAND A weight loss clinic with multiple locations in Kentucky, including Ashland, is facing accusations of providing patients with non-FDA approved semaglutide — falsely advertising a compounded ...

Tirzepatide, the newest weight loss drug in India, is transforming the wellness market with its hormone-mimicking effects.

Northern Ireland will open its first specialist weight management service next year, which will provide access to obesity drugs such as glucagon-like peptide-1 receptor agonists, health minister Mike ...

Amble Health's website states it is a platform connecting patients to licensed healthcare professionals online, who can ...

Oral delivery of proteins and peptides has historically faced significant technical barriers due to the enzymatic degradation and poor permeability of macromolecules in the gastrointestinal (GI) tract ...

More than a dozen lawsuits have been filed on behalf of weight-loss drug users who claim that popular weight-loss medications ...

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...